#None #AliveDx #MosaiQ AiPlex #Vasculitis

The Launch of MosaiQ AiPlex®: Transforming Vasculitis Diagnostics

In a significant advancement for autoimmune disease diagnostics, AliveDx, a global leader in in vitro diagnostics, has officially launched its MosaiQ AiPlex® Vasculitis assay (VAS) for clinical utilization within the European Union and other countries recognizing the IVDR-CE mark. This innovative test is designed specifically to enhance the speed and accuracy of diagnosing various forms of vasculitis, particularly those associated with anti-neutrophil cytoplasmic antibodies (ANCA) and Goodpasture's disease.

Significance of the MosaiQ AiPlex® Assay

On August 4th, 2025, AliveDx announced that the MosaiQ AiPlex VAS assay had successfully obtained IVDR-CE certification. This milestone enables healthcare professionals to access a state-of-the-art tool that simplifies autoimmune serological evaluations through a streamlined workflow. The MosaiQ AiPlex VAS assay allows for the testing of crucial autoantibody markers (MPO, PR3, and GBM) using just 10 μl of patient serum, thus providing comprehensive results in a single report. This approach not only aligns with recent clinical guidelines—such as the ACR/EULAR 2022 recommendations—but also offers faster diagnostic capabilities that are vital in managing serious diseases like vasculitis.

Understanding Vasculitis and Its Challenges

Vasculitis encompasses a spectrum of complex disorders characterized by the inflammation of blood vessel walls, which can lead to significant organ and tissue damage if left untreated. Conditions such as granulomatosis with polyangiitis (previously known as Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis present unique challenges for timely diagnosis due to varying symptoms and organ involvement. As such, the availability of a rapid and reliable testing method like the MosaiQ AiPlex VAS is indispensable in improving patient outcomes and facilitates healthcare providers in making informed decisions quickly.

How Does MosaiQ AiPlex® Work?

The MosaiQ AiPlex VAS assay stands out due to its multiplex testing capabilities, which automate and expedite the process of evaluating multiple serological markers simultaneously. This system not only rockets down the time healthcare professionals spend awaiting results but also minimizes manual handling and the chances of error through automated workflows. Additionally, the incorporation of radio-frequency identification (RFID) technology streamlines lab processes further by ensuring that reagents and test components are accurately tracked and utilized efficiently.

Manuel O. Méndez, the CEO of AliveDx, emphasized the impact of this new assay, stating, "Our MosaiQ technology provides fully automated multiplex test results quickly, significantly shortening turnaround times for diagnoses of autoimmune diseases. This CE marking achievement is a pivotal step in our goal to deliver premium health solutions to healthcare professionals and patients throughout Europe."

About AliveDx and Its Vision

With over 30 years of experience in the field, AliveDx is committed to revolutionizing patient care through innovative diagnostics. The company is focused on addressing the myriad complexities associated with autoimmune diseases and allergies. AliveDx's portfolio includes leading brands like Alba, MosaiQ, and LumiQ, designed to optimize laboratory workflows and deliver swift, precise results that improve clinical decision-making.

The MosaiQ AiPlex® platform exemplifies this commitment to excellence, featuring a user-friendly design aimed at enhancing both efficiency and diagnostic accuracy. By integrating state-of-the-art technology within its tests, AliveDx is ensuring that healthcare providers are well-equipped to meet the rising demand for fast and dependable diagnostics in a rapidly evolving medical landscape.

Conclusion

As the healthcare community embraces the MosaiQ AiPlex® Vasculitis assay, it marks a crucial point in enhancing the diagnostic protocols for autoimmune diseases. Through technological advancements and an unwavering commitment to quality, AliveDx is set to influence the future of diagnostic testing significantly. For further details about the MosaiQ AiPlex® and other innovative diagnostic solutions, visit AliveDx's official website and connect with them on their social channels.